Publicaciones en colaboración con investigadores/as de Université Catholique de Louvain (27)

2023

  1. [18F]DCFPyL PET/CT versus [18F]fluoromethylcholine PET/CT in Biochemical Recurrence of Prostate Cancer (PYTHON): a prospective, open label, cross-over, comparative study

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 50, Núm. 11, pp. 3439-3451

2022

  1. Tuning Database-Friendly Random Projection Matrices for Improved Distance Preservation on Specific Data

    Applied Intelligence, Vol. 52, Núm. 5, pp. 4927-4939

2021

  1. Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML (Leukemia, (2021), 35, 7, (2119-2124), 10.1038/s41375-021-01125-4)

    Leukemia

  2. Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, Núm. 11, pp. 785-798

  3. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  4. Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML

    Leukemia

2020

  1. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial

    The Lancet, Vol. 395, Núm. 10218, pp. 132-141

2019

  1. Class-aware t-SNE: Cat-SNE

    ESANN 2019 - Proceedings, 27th European Symposium on Artificial Neural Networks, Computational Intelligence and Machine Learning

2018

  1. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma

    New England Journal of Medicine, Vol. 378, Núm. 6, pp. 518-528

  2. Rituximab plus lenalidomide in advanced untreated follicular lymphoma

    New England Journal of Medicine, Vol. 379, Núm. 10, pp. 934-946

2016

  1. Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356

    Autophagy

  2. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

    Autophagy, Vol. 12, Núm. 1, pp. 1-222

  3. Intermittent versus continuous androgen deprivation therapy in patients with relapsing or locally advanced prostate cancer: A Phase 3b Randomised Study (Iceland)

    European Urology, Vol. 69, Núm. 4, pp. 720-727

  4. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): A phase 3b study in refractory multiple myeloma

    Blood, Vol. 128, Núm. 4, pp. 497-503

2012

  1. Guidelines for the use and interpretation of assays for monitoring autophagy

    Autophagy, Vol. 8, Núm. 4, pp. 445-544

2011

  1. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomised controlled trial

    The Lancet, Vol. 377, Núm. 9759, pp. 42-51

2008

  1. The flavonoid silibinin decreases glucose-6-phosphate hydrolysis in perifused rat hepatocytes by an inhibitory effect on glucose-6-phosphatase (Cellular Physiology and Biochemistry (2007) 20, 6, (925-934))

    Cellular Physiology and Biochemistry

2007

  1. Ontogenic development-associated changes in the expression of genes involved in rat bile acid homeostasis

    Journal of Lipid Research, Vol. 48, Núm. 6, pp. 1362-1370

  2. The flavonoid silibinin decreases glucose-6-phosphate hydrolysis in perifused rat hepatocytes by an inhibitory effect on glucose-6-phosphatase

    Cellular Physiology and Biochemistry, Vol. 20, Núm. 6, pp. 925-934

2002

  1. Functional profiling of the Saccharomyces cerevisiae genome

    Nature, Vol. 418, Núm. 6896, pp. 387-391